Valuation: 2cureX AB

Market Cap 7.43M 776K 675K 630K 578K 1.09M 74.01M 1.11M 2.91M 36.91M 2.92M 2.85M 122M P/E 2022
-4.81x
P/E 2023 -1.09x
Enterprise Value -5.97M -624K -543K -507K -465K -877K -59.52M -892K -2.34M -29.68M -2.35M -2.29M -97.9M EV / Sales 2022
29.3x
EV / Sales 2023 7.46x
Free-Float
61.98%
Yield 2022 *
-
Yield 2023 -
1 day-1.50%
1 week-5.65%
Current month-1.50%
1 month-14.90%
3 months-6.17%
6 months-12.04%
Current year+231.13%
1 week 1.7
Extreme 1.7
1.82
1 month 1.7
Extreme 1.7
2.08
Current year 0.52
Extreme 0.52
3.27
1 year 0.51
Extreme 0.514
4.2
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 01/01/2006
Chief Executive Officer 73 -
Chief Executive Officer 50 29/12/2023
Director TitleAgeSince
Chairman 73 16/12/2024
Director/Board Member 67 01/01/2006
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.50%-5.65%-31.37%-60.33% 5.68M
-3.17%-19.35%+89.72%+76.02% 3.61B
+2.39%+2.53%+123.72%+231.56% 3.68B
+9.47%+31.60%+291.57%+345.95% 2.48B
-0.42%+0.96%-27.65%-36.82% 2.16B
+6.02%-11.94%+61.01%-40.32% 1.93B
-2.28%-4.04%+189.19%-46.77% 947M
-0.74%-5.32%-8.09%+5.95% 850M
+1.46%+5.42%-37.98%-11.28% 519M
+2.80%-3.38%+2.52% - 464M
Average +1.40%+0.26%+65.26%+51.55% 1.66B
Weighted average by Cap. +1.85%+0.05%+102.93%+110.07%

Financials

2022 2023
Net sales 3.37M 352K 306K 286K 262K 495K 33.56M 503K 1.32M 16.74M 1.32M 1.29M 55.21M 2.95M 308K 268K 250K 229K 433K 29.36M 440K 1.15M 14.64M 1.16M 1.13M 48.29M
Net income -29.77M -3.11M -2.7M -2.52M -2.32M -4.37M -297M -4.45M -11.66M -148M -11.69M -11.43M -488M -32.52M -3.4M -2.95M -2.76M -2.53M -4.77M -324M -4.86M -12.74M -162M -12.77M -12.48M -533M
Net Debt -44.89M -4.69M -4.08M -3.81M -3.5M -6.59M -447M -6.71M -17.58M -223M -17.63M -17.24M -736M -13.4M -1.4M -1.22M -1.14M -1.04M -1.97M -134M -2M -5.25M -66.59M -5.26M -5.15M -220M
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
Date Price Change Volume
03/08/26 SEK 1.702 -1.50% 6,115
31/07/26 SEK 1.728 -0.12% 6,963
30/07/26 SEK 1.730 -2.15% 13,326
29/07/26 SEK 1.768 -2.96% 18,693
28/07/26 SEK 1.822 +1.00% 24,369
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock